We are live on ! Find out more
MRKR icon

Marker Therapeutics
MRKR

27 hedge funds and large institutions have $14.1M invested in Marker Therapeutics in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,600% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 1

1,142% more capital invested

Capital invested by funds: $1.14M → $14.1M (+$13M)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

145% more funds holding

Funds holding: 11 → 27 (+16)

8.54% more ownership

Funds ownership: 3.19% → 11.73% (+8.5%)

Holders
27
Holders Change
+16
Holders Change %
+145.45%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
17
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$1.7M
2
CH
CVI Holdings
Delaware
+$1.27M
3
6CM
683 Capital Management
New York
+$1.02M
4
RI
RTW Investments
New York
+$1.02M
5
CC
Caxton Corporation
New Jersey
+$432K

Top Sellers

Rank Fund Capital Flow
1
NRS
Neville Rodie & Shaw
New York
-$469K
2
BFM
Boston Financial Management
Massachusetts
-$206K

MRKR Hedge Fund Activity: Q2 2018 in Review

27 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2018, worth a combined $14.1M — up 1,142% from $1.14M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new MRKR positions and 1 closed out — a net gain of 16 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $1.7M. The largest seller was Neville Rodie & Shaw, cutting an estimated $469K.

  • 27 institutional investors held Marker Therapeutics (MRKR) as of Q2 2018, up from 11 in Q1 2018.
  • Funds reported $14.1M of Marker Therapeutics stock for Q2 2018, up 1,142% quarter-over-quarter.
  • 17 funds opened new Marker Therapeutics positions in Q2 2018 and 1 closed out, a net change of +16 holders.
  • The largest Marker Therapeutics buyer in Q2 2018 was Driehaus Capital Management, an estimated $1.7M added.
  • The largest Marker Therapeutics seller in Q2 2018 was Neville Rodie & Shaw, an estimated $469K sold.

Based on aggregated 13F filings for Q2 2018.